Table 1 Baseline characteristics in trials retained for the final analysis
Author | Antibiotic regimen | Funding | Nb of patients*, N | Male gender, N | Age, mean ± SD | VAP, N | Bacteraemia | Apache II score, mean ± SD | Renal failure (Cl < 60 ml/min) | Documented pathogens (GNB) | K. pneumoniae | E. coli | P. aeruginosa | A. baumanii | No documentation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Titov et al | Imipenem/Cilastatin/Relebactam | Funded | 264 | 178 | 60.5 ± 16.9 | 122 | 15 | 14.6 ± 6.2 | 71 | 215 | 58 | 30 | 34 | 32 | 49 |
Piperacillin/Tazobactam | Funded | 267 | 189 | 58.8 ± 18.4 | 136 | 16 | 14.8 ± 6.7 | 60 | 218 | 53 | 37 | 48 | 36 | 49 | |
Zanetti et al | Cefepime | Funded | 108 | 72 | 55 ± 18 | 66 | NA | 15.6 ± 6.6 | NA | 77 | 18 | 7 | 23 | 12 | 31 |
Imipenem/Cilastatin | Funded | 101 | 67 | 53 ± 18 | 66 | NA | 14.8 6.3 | NA | 71 | 16 | 2 | 29 | 8 | 31 | |
Wunderink et al | Cefiderocol | Funded | 145 | 99 | 64.6 ± 14.6 | 58 | NA | 16 ± 6.1 | 47 | 113 | 48 | 19 | 24 | 23 | 20 |
Meropenem | Funded | 147 | 101 | 65.4 ± 15.1 | 63 | NA | 16.4 ± 6.9 | 51 | 105 | 44 | 22 | 24 | 24 | 19 | |
Torres et al | Ceftazidime/Avibactam | Funded | 356 | 268 | 62.1 ± 16.6 | 118 | 19 | 14.5 ± 4 | 18 | 173 | 37 | 11 | 42 | NA | 183 |
Meropenem | Funded | 370 | 274 | 61.9 ± 17.4 | 128 | 15 | 14.9 ± 4 | 18 | 188 | 49 | 18 | 35 | NA | 182 | |
Schmitt et al | Piperacillin/Tazobactam | Independent | 110 | 77 | 68.4 ± 13.7 | 31 | NA | 13.5 ± 4.2 | NA | NA | NA | NA | NA | NA | NA |
Imipenem/Cilastatin | Independent | 111 | 64 | 65.7 ± 13.8 | 21 | NA | 13.3 ± 4.3 | NA | NA | NA | NA | NA | NA | NA | |
Chastre et al | Doripenem | Independent | 126 | 102 | 50.7 ± 19.6 | 126 | 13 | NA | 13 | 92 | 15 | 12 | 20 | NA | 34 |
Imipenem/Cilastatin | Independent | 122 | 91 | 50.3 ± 19 | 122 | 11 | NA | 8 | 82 | 10 | 10 | 14 | NA | 30 | |
Kollef et al | Doripenem | Funded | 115 | 72 | 57.5 ± 16.5 | 115 | 6 | NA | 13 | 65 | 19 | 6 | 17 | 15 | 50 |
Imipenem/Cilastatin | Funded | 112 | 75 | 54.6 ± 18.5 | 112 | 5 | NA | 8 | 62 | 20 | 14 | 10 | 10 | 50 | |
Kollef et al | Ceftolozane/Tazobactam | Funded | 362 | 262 | 60.5 ± 16.7 | 362 | 25 | 17.5 ± 5.2 | 52 | 157 | 86 | 51 | 63 | 24 | 98 |
Meropenem | Funded | 364 | 255 | 59.5 ± 17.2 | 364 | 40 | 17.4 ± 5.7 | 48 | 137 | 91 | 42 | 65 | 14 | 117 | |
Cisneros et al | IV Colistin | Independent | 120 | 92 | 63 (IQR: 49–71) | 120 | 21 | 19 (IQR: 14–24) | 89 | 14 | 12 | 19 | 16 | 19 | |
Meropenem | Independent | 112 | 81 | 60.5 (IQR: 50–70) | 112 | 17 | 17 (13–22) | 85 | 15 | 8 | 15 | 18 | 19 | ||
Réa-Neto et al | Doripenem | Funded | 134 | 98 | 57.5 ± 19.2 | 105 | 8 | NA | 21 | 92 | 20 | 14 | 22 | 14 | NA |
Piperacillin/Tazobactam | Funded | 119 | 74 | 59.3 ± 18.9 | 93 | 17 | NA | 9 | 98 | 28 | 11 | 32 | 9 | NA | |
Yamamato et al | Piperacillin/Tazobactam | Funded | 34 | 18 | 77.6 | 0 | NA | NA | NA | 19 | 6 | 2 | 2 | NA | 15 |
Meropenem | Funded | 33 | 18 | 79.1 | 0 | NA | NA | NA | 18 | 1 | 0 | 4 | NA | 15 | |
Lerma et al | Meropenem | Funded | 69 | 47 | 61.5 ± 13.7 | 69 | NA | 16.5 ± 5.7 | NA | 44 | 5 | 6 | 14 | 3 | NA |
Ceftazidime | Funded | 71 | 56 | 62.3 ± 15.7 | 71 | NA | 16.6 ± 6 | NA | 34 | 2 | 3 | 13 | 2 | NA | |
Torres et al | Ciprofloxacin | Independent | 41 | 31 | 64 ± 14 | 41 | NA | 13.8 ± 7.5 | 2 | 41 | 1 | 1 | 14 | 6 | NA |
Imipenem/Cilastatin | Independent | 34 | 25 | 61 ± 17 | 34 | NA | 13.9 ± 8.6 | 0 | 34 | 1 | 1 | 12 | 3 | NA | |
Abdelsalam et al | Colistin (IV) | Independent | 30 | 16 | 56.2 ± 17.9 | 30 | NA | 18.1 ± 4 | 2 | 30 | 30 | 0 | 0 | 0 | 0 |
Meropenem + Colistin (AS) | Independent | 30 | 12 | 55.9 ± 15.6 | 30 | NA | 18.9 ± 5.5 | 4 | 30 | 30 | 0 | 0 | 0 | 0 | |
Alvarez-Lerma et al | Piperacillin/Tazobactam | Funded | 88 | 64 | 57.1 ± 17 | 75 | NA | 16.5 ± 6.6 | 4 | 64 | 1 | 5 | 14 | 2 | NA |
Ceftazidime | Funded | 36 | 26 | 60.5 ± 20 | 31 | NA | 16.9 ± 6.5 | 2 | 29 | 1 | 2 | 7 | 0 | NA | |
Joshi et al | Piperacillin/Tazobactam | Funded | 222 | 173 | 53.2 ± 19.1 | 157 | NA | 13.9 | NA | 155 | 14 | 5 | 18 | 9 | NA |
Imipenem/Cilastatin | Funded | 215 | 138 | 52.7 ± 20.9 | 143 | NA | 13 | NA | 121 | 12 | 10 | 17 | 8 | NA |